Lexeo Therapeutics Inc, a clinical-stage genetic medicine company based in New York City, went public on November 3, 2023, and employs 53 people. The company develops gene therapy candidates like LX2006 and LX2020 targeting rare cardiovascular diseases with unmet needs.
Lexeo Therapeutics (LXEO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Lexeo Therapeutics's actual EPS was -$0.64, beating the estimate of -$0.71 per share, resulting in a 9.26% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
